The last decade has seen the discovery and functional annotation of numerous high-confidence autism spectrum disorder (ASD) risk genes1-3. In the time since, much effort has been dedicated to understanding how these genes impact nervous system development. A consensus has emerged that many genes implicated in ASD susceptibility impact early steps in neurodevelopment, such as the timing and execution of neural differentiation, migration and synaptogenesis, with such cellular phenotypes thought to be rooted in altered epigenomic and transcriptomic landscapes4-9. In parallel, SFARI has invested in efforts to characterize the impact of ASD risk gene mutation on the neural circuits underlying ASD-relevant phenotypes, with notable advances made in understanding the contribution of peripheral and central circuits to ASD-related sensory atypicalities, motor phenotypes, sleep disruptions and social behavioral deficits, among other phenotypes10-13.

While progress has been made toward understanding early development and mature functional outcomes in isolation, studies causally linking disruptions of early neurodevelopment to alterations in ASD-relevant neural circuits remain rare. The objective of this RFA is to bridge this critical gap in our understanding of how developmental events impact later processes of circuit formation and function in ASD. We envision that this RFA will bring together scientists of diverse expertise, such as developmental neurobiologists and circuit neuroscientists, to collaboratively conduct thorough characterizations of how early developmental events result in alterations to ASD-relevant neural circuitry in carefully chosen models.

Scientific Priorities and Scope

The Linking Early Neurodevelopment to Neural Circuit Outcomes RFA will support research that aims to directly connect neurodevelopmental changes to ASD-relevant circuit phenotypes in order to advance our understanding of how ASD risk genes contribute to the neurobiology of autism. We invite proposals that will elucidate the impact of well-defined developmental alterations on the structure, function and/or output of neural circuits relevant to ASD phenotypes.

To this end, experimental endpoints need not be behavioral readouts, but should be phenotypes that would reasonably be expected to drive alterations in function at the organism level (e.g., changes in synaptic connectivity or plasticity, or altered local or mesoscale neural dynamics and/or coding, ideally assessed with cell-type specificity).

To facilitate rigorous assessments of causality, we imagine that successful applications will connect phenotypes at adjacent biological scales (e.g., from neuronal migration defect to aberrant connectivity or from aberrant connectivity to altered neural dynamics), linking across as many levels of analysis as possible within the time and budget provided by the grant. Because the goal of this RFA is to establish causal links between temporally distant phenotypes, we encourage dense and/or longitudinal sampling whenever appropriate, in order to rigorously characterize the relative timing and stability of the phenotypes of interest. Competitive applications will provide strong evidence in support of the chosen phenotypic starting point(s) in the form of published or high-quality preliminary data, as well as a statement of the direct relevance of the proposed work to ASD.

While we envision many successful projects will take a “forward” approach (starting with a developmental phenotype and following it to circuit function), we are open to considering proposals adopting a “reverse” approach (starting with a later-manifesting phenotype and working backward to uncover its developmental underpinnings), provided that the motivating phenotype is well established and that there is a specific and well-supported hypothesis regarding its potential developmental origin.

Whenever possible, we encourage applicants to demonstrate evolutionary conservation of their chosen phenotypes. We also encourage, but do not require, that studies consider convergence in the function of ASD risk genes within their proposed framework.

Because the work supported by this RFA is likely to be time-intensive and highly mechanistic in nature, the choice of experimental model(s) and risk gene(s) must be well justified. SFARI recognizes the critical contributions of in vitro systems such as organoids and slice preparations to our understanding of neurodevelopment and circuit function. While we are open to proposals utilizing such models, we feel that due to the inherent complexity of circuit formation and function in the intact nervous system, work in in vitro systems must be carefully justified and ideally accompanied by in vivo studies in order to achieve the goals of this RFA.

Level and Duration of Funding

Due to the multidisciplinary focus of this RFA, we strongly encourage collaborative applications involving multiple principal investigators (PIs); single PI applications will also be accepted. Each lab may request a maximum of $300,000, inclusive of 20 percent indirect costs, for each year of funding over a period of three (3) to four (4) years, up to an annual maximum of $900,000. Allowable indirect costs to the primary institution for subcontracts are not included in the total budget threshold (see grant policies).

We encourage investigators to take advantage of the flexibility in budget and duration, tailoring the scope of the award as appropriate for their specific aims. As with all SFARI-funded projects, it is at Simons Foundation’s discretion to modify final budgets as needed.

Recognizing that different stages of a project may have different personnel and financial requirements, the primary PI may adjust PI membership during the funding period to reflect scientific needs, with SFARI approval.

Progress will be critically evaluated at two (2) years before support for the remainder of the funding period will be approved, bearing in mind the potentially high-risk nature of the funded work. Adherence to an open-science ethos will be an important consideration in this assessment.

Please note that in the event of budgetary or other considerations, The Simons Foundation, Inc. reserves the right to refer an application that has advanced through scientific review to The Simons Foundation International, Ltd. (SFI) for consideration and funding, in which case SFI’s grant policies would apply.

Review Process

Applications will be evaluated by the SFARI science team, with a subset selected for further evaluation by an external review panel. Competitive applications will be invited to present their proposal via Zoom to the SFARI science team and invited scientists on January 14, 15 or 16, 2025.

Eligibility

All applicants and key collaborators must hold a Ph.D., M.D. or equivalent degree and have a faculty position or the equivalent at a college, university, medical school or other research facility.

SFARI recognizes the importance of diverse viewpoints for scientific advancement. As such, SFARI encourages the inclusion of researchers who span career stages and of groups historically underrepresented in science.

Applications may be submitted by domestic and foreign nonprofit organizations; public and private institutions, such as colleges, universities, hospitals, laboratories and units of state and local government; and eligible agencies of the federal government.

There are no citizenship or country requirements.

For More funding Opportunities, Visit Global Funding Opportunities.